Evidence map›Paper›PMID 38938854›Full record

ArticleJACC. Advances2024

Lipoprotein(a) Levels in Disaggregated Racial and Ethnic Subgroups Across Atherosclerotic Cardiovascular Disease Risk Levels.

Ramzi Dudum, Qiwen Huang, Xiaowei Sherry Yan, Marina Adrianzen Fonseca, Powell Jose, Ashish Sarraju, Latha Palaniappan, Fatima Rodriguez

Abstract read
In one paragraph

Article in JACC. Advances, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 15 papers.

0numbers the graph read from it
0cells of the map it votes in
15citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

15 citing papers in PubMed.

  1. Article
  2. Article
  3. Article
  4. Review
  5. Review
  6. Article
  7. Article
  8. Observational
  9. Review
  10. Review
  11. Article
  12. Review
  13. Article
  14. Novel Circulating Biomarkers in Aortic Valve Stenosis.International journal of molecular sciences · 2025
    Review
  15. JACC. Advances · 2024
    Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

8 authors.

Ramzi DudumDivision of Cardiovascular Medicine and Cardiovascular Institute, Stanford University, Stanford, California, USA.
Qiwen HuangCenter for Health Systems Research and Palo Alto Medical Foundation Research Institute, Sutter Health, Palo Alto, California, USA.
Xiaowei Sherry YanCenter for Health Systems Research and Palo Alto Medical Foundation Research Institute, Sutter Health, Palo Alto, California, USA.
Marina Adrianzen FonsecaDepartment of Medicine, University of Wisconsin, Madison, Wisconsin, USA.
Powell JoseSutter Medical Group, Department of Cardiology, Sacramento, California, USA.
Ashish SarrajuDepartment of Cardiovascular Medicine, Cleveland Clinic, Cleveland, Ohio, USA.
Latha PalaniappanDivision of Cardiovascular Medicine and Cardiovascular Institute, Stanford University, Stanford, California, USA.
Fatima RodriguezDivision of Cardiovascular Medicine and Cardiovascular Institute, Stanford University, Stanford, California, USA.

Funding

Adherence Determinants in the Health Electronic Record Evaluation of Statins (ADHERES)R01HL168188 · NHLBI · STANFORD UNIVERSITY · PI Fatima Rodriguez · 2024 to 2026
$2.1M
SURPASS: (Statin Use and Risk Prediction of Atherosclerotic Cardiovascular Disease in minority Subgroups)K01HL144607 · NHLBI · STANFORD UNIVERSITY · PI RODRIGUEZ, FATIMA · 2019 to 2023
$856k
NHLBI NIH HHS K01 HL144607NHLBI NIH HHS R01 HL168188
6 · The paper itself

Abstract

Background: Lipoprotein(a) [Lp(a)] is a causal risk factor for atherosclerotic cardiovascular disease (ASCVD). Objectives: The authors assessed differences in Lp(a) testing and levels by disaggregated race, ethnicity, and ASCVD risk. Methods: This was a retrospective cohort study of patients from a large California health care system from 2010 to 2021. Eligible individuals were ≥18 years old, with ≥2 primary care visits, and complete race and ethnicity data who underwent Lp(a) testing. Race and ethnicity were self-reported and categorized as follows: non-Hispanic (NH) White, NH-Black, Hispanic (Mexican, Puerto Rican, other), NH-Asian (Asian Indian, Chinese, Filipino, Japanese, Korean, Vietnamese, other). Logistic regression models tested associations between elevated Lp(a) (≥50 mg/dL) and race, ethnicity, and ASCVD risk. Results: 13,689 (0.9%) individuals underwent Lp(a) testing with a mean age of 54.6 ± 13.8 years, 49% female, 28.8% NH Asian. Over one-third of those tested had Lp(a) levels ≥50 mg/dL, ranging from 30.7% of Mexican patients to 62.6% of NH-Black patients. The ASCVD risk of those tested varied by race: 73.6% of Asian Indian individuals had <5% 10-year risk, whereas 27.2% of NH-Black had established ASCVD. Lp(a) prevalence ≥50 mg/dL increased across the ASCVD risk spectrum. After adjustment, Hispanic (OR: 0.76 [95% CI: 0.66-0.88]) and Asian (OR: 0.88 [95% CI: 0.81-0.96]) had lower odds of Lp(a) ≥50 mg/dL, whereas Black individuals had higher odds (OR: 2.46 [95% CI: 1.97-3.07]). Conclusions: Lp(a) testing is performed infrequently. Of those tested, Lp(a) levels were frequently elevated and differed significantly across disaggregated race and ethnicity groups. The prevalence of elevated Lp(a) increased with increasing ASCVD risk, with significant variation by race and ethnicity.

Indexed as

ethnicitylipoprotein(a)racetesting

Identifiers

PMID38938854
PMCPMC11198068

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.